| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
2'-Deoxy-2'-fluorouridine targets viral polymerases and can be used as an intermediate in the preparation of anti-influenza virus reagents. As a nucleoside analog, it interferes with viral polymerase activity, allowing mechanistic study of genome replication. The compound is incorporated into therapeutic oligonucleotides to combat prostate and breast cancer. Its mechanism involves inhibition of viral RNA/DNA synthesis through interference with polymerase activity.
|
|---|---|
| ln Vitro |
2'-Deoxy-2'-fluorouridine demonstrates in vitro activity as a nucleoside analog. It serves as an intermediate in the synthesis of antiviral agents targeting influenza viruses. The compound is a component incorporated into therapeutic oligonucleotides to combat prostate and breast cancer. Its activity is typically assessed in antiviral assays measuring influenza virus replication and in cellular assays measuring cancer cell proliferation.
|
| ln Vivo |
In vivo studies for 2'-Deoxy-2'-fluorouridine have not been extensively documented in the available literature. As a nucleoside analog and antiviral intermediate, it has potential for in vivo applications in the treatment of influenza and cancer. Studies in appropriate animal models would be needed to evaluate its in vivo efficacy, pharmacokinetics, and safety profile. The compound is incorporated into therapeutic oligonucleotides.
|
| Enzyme Assay |
For antiviral activity assays, 2'-Deoxy-2'-fluorouridine is tested against influenza viruses at various concentrations. Viral replication is assessed by measuring viral titers, plaque formation, or viral RNA levels. IC50 values are calculated from dose-response curves. For polymerase inhibition assays, viral polymerase is incubated with the compound and polymerase activity is measured. For cancer cell studies, cell viability is assessed using MTT assays.
|
| Cell Assay |
For cellular studies, appropriate cell lines (e.g., influenza virus-infected cells or cancer cell lines) are cultured in appropriate media and treated with 2'-Deoxy-2'-fluorouridine at various concentrations. For antiviral studies, cells are infected with influenza virus and treated with the compound. Viral replication is assessed by qRT-PCR or plaque assays. For cancer studies, cell viability is assessed using MTT or CellTiter-Glo assays. Cytotoxicity is assessed in parallel.
|
| Animal Protocol |
For in vivo efficacy studies, appropriate animal models of influenza infection or cancer would be used. 2'-Deoxy-2'-fluorouridine would be administered via appropriate routes at various doses. Viral load in lung tissues or tumor volume would be measured. Pharmacokinetic parameters including half-life, clearance, and tissue distribution would be determined. However, detailed in vivo protocols for 2'-Deoxy-2'-fluorouridine have not been extensively reported.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 2'-Deoxy-2'-fluorouridine have not been fully characterized in the available literature. The compound has a molecular formula of C9H11FN2O5 and a molecular weight of 246.19. Purity is min. 97.0% by HPLC and min. 95.0% by neutralization titration. Melting point is 147.0 to 153.0°C. Appearance is white to almost white powder to crystal. Storage at room temperature in a cool and dark place (<15°C) is recommended.
|
| Toxicity/Toxicokinetics |
2'-Deoxy-2'-fluorouridine is a research compound intended for laboratory use only and is not approved for human therapeutic use. As a nucleoside analog, it serves as an intermediate in the synthesis of anti-influenza virus reagents and is incorporated into therapeutic oligonucleotides. Standard laboratory safety precautions should be followed when handling this compound. Purity min. 97.0% by HPLC.
|
| References | |
| Additional Infomation |
2'-Deoxy-2'-fluorouridine is a nucleoside analog with molecular formula C9H11FN2O5 and molecular weight 246.19. It serves as an intermediate in the synthesis of anti-influenza virus reagents and is incorporated into therapeutic oligonucleotides to combat prostate and breast cancer. The compound interferes with viral polymerase activity. It is for research use only and has not been approved for clinical applications. Purity min. 97.0% by HPLC and storage at room temperature in a cool, dark place (<15°C) is recommended.
|
| Molecular Formula |
C9H11FN2O5
|
|---|---|
| Molecular Weight |
246.19
|
| Exact Mass |
246.065
|
| CAS # |
784-71-4
|
| Related CAS # |
2'-Deoxy-2'-fluorouridine-d2;362049-50-1
|
| PubChem CID |
150851
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Melting Point |
151 °C
|
| Index of Refraction |
1.608
|
| LogP |
-1.31
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
17
|
| Complexity |
374
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CN(C(=O)NC1=O)[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)F
|
| InChi Key |
UIYWFOZZIZEEKJ-XVFCMESISA-N
|
| InChi Code |
InChI=1S/C9H11FN2O5/c10-6-7(15)4(3-13)17-8(6)12-2-1-5(14)11-9(12)16/h1-2,4,6-8,13,15H,3H2,(H,11,14,16)/t4-,6-,7-,8-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (406.19 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (10.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.0619 mL | 20.3095 mL | 40.6190 mL | |
| 5 mM | 0.8124 mL | 4.0619 mL | 8.1238 mL | |
| 10 mM | 0.4062 mL | 2.0310 mL | 4.0619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
